On September 20, 2020 the Royal Marsden NHS Foundation Trust made known of a recent study involving over 5,000 people for two years. The study’s results showed a 25% reduction in cancer recurrence with those in the high risk category of early hormone receptor positive (HR+) human epidermal growth factor 2 negative (HER2-) breast cancer.
Professor Stephen Johnston, from the Royal Marsden commented by saying: “This is the first time in more than 20 years that we have seen an advance in the adjuvant treatment of this form of breast cancer”. The professor also said that this form of is the most common form of breast cancer. One of the biggest concerns with those who have had to deal with breast cancer, and having the cancer go into remission, is that of recurrence.
Researcher Jonhston is also quoted with saying “We found a 25% reduction in recurrence of cancer with the first two years when abemaciclib was added to hormone therapy compared to hormone therapy alone”.
Giuseppe Curigliano, Associate Professor of Medical Oncology at the University of Milan, Italy, and Chair of the ESMO Guidelines Committee. is quoted by saying: “This is the first study to show that adding a CDK4/6 inhibitor to endocrine therapy significantly improves invasive disease free survival in the adjuvant setting.
This is a very important trial and the findings will change practice. Once approved for high risk HR+ HER2- early breast cancer the new standard of care for these patients will be to add two years of abemaciclib to endocrine therapy,”
There were 16.6% of the people or 463 who had to discontinue the treatments with abemaciclib because experiencing side effects. This is an unfortunate number. We hope the researchers can find ways to minimize these side effects. At the same time, we are truly grateful for those who able t take this medication.
This treatment is not the cure we all are looking for, but it certainly gives hope to thousands if not millions of people around the globe.